{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:54:59Z","timestamp":1770742499776,"version":"3.49.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.dmpk.2022.100459","type":"journal-article","created":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T03:10:17Z","timestamp":1647659417000},"page":"100459","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Species differences between rats and primates (humans and monkeys) in complex cleavage pathways of DS-8500a characterized by 14C-ADME studies in humans and monkeys after administration of two radiolabeled compounds and in\u00a0vitro studies"],"prefix":"10.1016","volume":"45","author":[{"given":"Chie","family":"Makino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7496-5911","authenticated-orcid":false,"given":"Akiko","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Shiozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Takakusa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyo","family":"Honda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2103-7078","authenticated-orcid":false,"given":"Nobuaki","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.dmpk.2022.100459_bib1","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2017-000424","article-title":"Glucose-lowering effects and safety of DS-8500a, a G protein-coupled receptor 119 agonist, in Japanese patients with type 2 diabetes: results of a randomized, double-blind, placebo-controlled, parallel-group, multicenter, phase II study","volume":"5","author":"Inagaki","year":"2017","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"6","key":"10.1016\/j.dmpk.2022.100459_bib2","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s40261-018-0633-5","article-title":"Safety and pharmacokinetics of DS-8500a, a novel GPR119 agonist, after multiple oral doses in healthy Japanese males","volume":"38","author":"Kato","year":"2018","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.dmpk.2022.100459_bib3","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1124\/jpet.118.250019","article-title":"DS-8500a, an orally available G protein-coupled receptor 119 agonist, upregulates glucagon-like peptide-1 and enhances glucose-dependent insulin secretion and improves glucose homeostasis in type 2 diabetic rats","volume":"367","author":"Matsumoto","year":"2018","journal-title":"J\u00a0Pharmacol Exp Therapeut"},{"issue":"8","key":"10.1016\/j.dmpk.2022.100459_bib4","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1080\/00498254.2018.1514545","article-title":"In\u00a0vivo multiple metabolic pathways for a novel G protein-coupled receptor 119 agonist DS-8500a in rats: involvement of the 1,2,4-oxadiazole ring-opening reductive reaction in livers under anaerobic conditions","volume":"49","author":"Makino","year":"2019","journal-title":"Xenobiotica"},{"issue":"6","key":"10.1016\/j.dmpk.2022.100459_bib5","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/jms.1033","article-title":"Interspecies in\u00a0vitro metabolism of the phosphodiesterase-4 (PDE4) inhibitor L-454,560","volume":"41","author":"Bateman","year":"2006","journal-title":"J\u00a0Mass Spectrom"},{"issue":"6","key":"10.1016\/j.dmpk.2022.100459_bib6","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1124\/dmd.112.044636","article-title":"Metabolism of a G protein-coupled receptor modulator, including two major 1,2,4-oxadiazole ring-opened metabolites and a rearranged cysteine-piperazine adduct","volume":"40","author":"Gu","year":"2012","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmpk.2022.100459_bib7","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3109\/00498257309151504","article-title":"Metabolic studies with trans-5-amino-3-(2-(5-nitro-2-furyl)vinyl)-1,2,4-(5-14C)oxadiazole (SQ 18,506). 1. Reductive cleavage of the 1,2,4-oxadiazole ring","volume":"3","author":"Lan","year":"1973","journal-title":"Xenobiotica"},{"issue":"1","key":"10.1016\/j.dmpk.2022.100459_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/bms.1200230102","article-title":"The use of liquid chromatography\/thermospray mass spectrometry with on-line ultraviolet diode array and radiochemical detection: characterization of the putative metabolites of U-78875 in female rat faeces","volume":"23","author":"Speed","year":"1994","journal-title":"Biol Mass Spectrom"},{"issue":"5","key":"10.1016\/j.dmpk.2022.100459_bib9","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1124\/dmd.120.000220","article-title":"Absorption, metabolism, and excretion, in\u00a0vitro pharmacology, and clinical pharmacokinetics of ozanimod, a novel sphingosine 1-phosphate receptor modulator","volume":"49","author":"Surapaneni","year":"2021","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"10.1016\/j.dmpk.2022.100459_bib10","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1124\/dmd.110.036467","article-title":"Metabolism of [(14)C]GSK977779 in rats and its implication with the observed covalent binding","volume":"39","author":"Tsalta","year":"2011","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.dmpk.2022.100459_bib11","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0090-9556(25)08160-7","article-title":"Rat liver microsomal cytochrome P-450 responsible for reductive metabolism of zonisamide","volume":"21","author":"Nakasa","year":"1993","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmpk.2022.100459_bib12","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0026-895X(25)13151-9","article-title":"Characterization of human liver microsomal cytochrome P450 involved in the reductive metabolism of zonisamide","volume":"44","author":"Nakasa","year":"1993","journal-title":"Mol Pharmacol"},{"issue":"2","key":"10.1016\/j.dmpk.2022.100459_bib13","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0090-9556(25)07297-6","article-title":"Involvement of mammalian liver cytosols and aldehyde oxidase in reductive metabolism of zonisamide","volume":"24","author":"Sugihara","year":"1996","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmpk.2022.100459_bib14","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1124\/dmd.107.018416","article-title":"Reductive isoxazole ring opening of the anticoagulant razaxaban is the major metabolic clearance pathway in rats and dogs","volume":"36","author":"Zhang","year":"2008","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmpk.2022.100459_bib15","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0090-9556(25)08286-8","article-title":"The metabolism and excretion of risperidone after oral administration in rats and dogs","volume":"22","author":"Meuldermans","year":"1994","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.dmpk.2022.100459_bib16","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0090-9556(25)08211-X","article-title":"Absorption, metabolism, and excretion of risperidone in humans","volume":"21","author":"Mannens","year":"1993","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmpk.2022.100459_bib17","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.2042-7158.1997.tb06790.x","article-title":"The role of mammalian intestinal bacteria in the reductive metabolism of zonisamide","volume":"49","author":"Kitamura","year":"1997","journal-title":"J\u00a0Pharm Pharmacol"},{"issue":"1","key":"10.1016\/j.dmpk.2022.100459_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/00498259209053097","article-title":"Reductive metabolism of the anticonvulsant agent zonisamide, a 1,2-benzisoxazole derivative","volume":"22","author":"Stiff","year":"1992","journal-title":"Xenobiotica"},{"key":"10.1016\/j.dmpk.2022.100459_bib19","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.bcp.2016.07.007","article-title":"Human arylacetamide deacetylase hydrolyzes ketoconazole to trigger hepatocellular toxicity","volume":"116","author":"Fukami","year":"2016","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.dmpk.2022.100459_bib20","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.bcp.2016.07.007","article-title":"Human arylacetamide deacetylase hydrolyzes ketoconazole to trigger hepatocellular toxicity","volume":"116","author":"Fukami","year":"2016","journal-title":"Biochem Pharmacol"},{"issue":"7","key":"10.1016\/j.dmpk.2022.100459_bib21","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1124\/dmd.114.056994","article-title":"Screening of specific inhibitors for human carboxylesterases or arylacetamide deacetylase","volume":"42","author":"Shimizu","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2022.100459_bib22","doi-asserted-by":"crossref","first-page":"100397","DOI":"10.1016\/j.dmpk.2021.100397","article-title":"Epicatechin gallate and epigallocatechin gallate are potent inhibitors of human arylacetamide deacetylase","volume":"39","author":"Yasuda","year":"2021","journal-title":"Drug Metabol Pharmacokinet"},{"issue":"4","key":"10.1016\/j.dmpk.2022.100459_bib23","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0031-6997(25)06622-0","article-title":"Metabolism of foreign compounds by gastrointestinal microorganisms","volume":"25","author":"Scheline","year":"1973","journal-title":"Pharmacol Rev"},{"issue":"1","key":"10.1016\/j.dmpk.2022.100459_bib24","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1527-3458.2006.00021.x","article-title":"Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597)","volume":"12","author":"Piomelli","year":"2006","journal-title":"CNS Drug Rev"},{"issue":"6604","key":"10.1016\/j.dmpk.2022.100459_bib25","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/384083a0","article-title":"Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides","volume":"384","author":"Cravatt","year":"1996","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.dmpk.2022.100459_bib26","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1021\/jp5052276","article-title":"Anandamide hydrolysis in FAAH reveals a dual strategy for efficient enzyme-assisted amide bond cleavage via nitrogen inversion","volume":"119","author":"Palermo","year":"2015","journal-title":"J\u00a0Phys Chem B"},{"issue":"1","key":"10.1016\/j.dmpk.2022.100459_bib27","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1021\/acs.jmedchem.6b00538","article-title":"Therapeutic potential of fatty acid amide hydrolase, monoacylglycerol lipase, and N-acylethanolamine acid amidase inhibitors","volume":"60","author":"Tuo","year":"2017","journal-title":"J\u00a0Med Chem"},{"issue":"48","key":"10.1016\/j.dmpk.2022.100459_bib28","doi-asserted-by":"crossref","first-page":"36569","DOI":"10.1074\/jbc.M606646200","article-title":"A\u00a0second fatty acid amide hydrolase with variable distribution among placental mammals","volume":"281","author":"Wei","year":"2006","journal-title":"J\u00a0Biol Chem"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436722000167?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436722000167?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:56:53Z","timestamp":1761163013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436722000167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":28,"alternative-id":["S1347436722000167"],"URL":"https:\/\/doi.org\/10.1016\/j.dmpk.2022.100459","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Species differences between rats and primates (humans and monkeys) in complex cleavage pathways of DS-8500a characterized by 14C-ADME studies in humans and monkeys after administration of two radiolabeled compounds and in\u00a0vitro studies","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Pharmacokinetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmpk.2022.100459","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100459"}}